Skip to Content
Merck
  • Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa).

Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa).

The Journal of steroid biochemistry and molecular biology (2009-01-14)
Anne Ørbo, Bjørn T Moe, Halvor Grønaas, Ruth H Paulssen
ABSTRACT

Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine device which showed to induce endometrial atrophy. The intention of the present study was to obtain more information of novel therapeutic targets for hormonal treatment in endometrial hyperplasia and endometrial cancers. Gene expression of signaling pathways after stimulation of Ishikawa cells with high doses of progesterone (32 microM) or Mifepristone (32 microM) was performed. After using an oligo microarrays representing 24,650 human genes and 37,580 gene transcripts, 6154 genes remained after pre-processing and filtering. This resulted in a total of 993 up-regulated genes with 189 genes for progesterone and 255 genes for Mifepristone. The 550 down-regulated genes were distributed with 256 genes for progesterone, 127 genes for RU 486. The results showed that genes presenting the epidermal growth factor (EGF)/MAP-kinase pathway were significantly over-represented by progesterone treatment, whereas, by Mifepristone treatment genes involved in the p53 pathway were also up-regulated (data not shown). These genes may be interesting as potential new therapeutic targets in endometrial hyperplasia and endometrial cancer, as candidate genes for therapy response or as candidate markers for tumor progression.

MATERIALS
Product Number
Brand
Product Description

Supelco
ORBO 90 Carboxen® 564 (20/45), 160/80 mg, W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group MEK (methylethyl ketone)
Supelco
ORBO 80 Isocyanate Filter, with cassettes: no, filter O.D. 37 mm, pkg of 25 ea
Supelco
ORBO 65P (OVS) Amberlite XAD®-4 specially cleaned, 160/80 mg, RC,GFF,F,F (specially cleaned) separators, O.D. × L 13-8 mm × 75 mm , OSHA Versatile Sampler (OVS), pkg of 10 ea
Supelco
ORBO 92 Carboxen® 564 (20/45), 160/80 mg, W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group Vinyl acetate
Supelco
ORBO 52 Small Activated Silica Gel (20/40) 150/75 mg, pk 50, W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Supelco
ORBO 43 Supelpak-20 specially treated Amberlite XAD®-2 (20/40), 100/50 mg, W,W,W (specially treated) separators, O.D. × L 8 mm × 100 mm, pkg of 50 ea
Supelco
ORBO 24 2-HMP on Amberlite XAD®-2 (20/40), 150/75 mg, W,W,W separators, O.D. × L 6 mm × 105 mm, pkg of 25 ea
Supelco
ORBO 402 Tenax® TA specially treated (35/60), 100/50 mg, W,W,W separators, O.D. × L 8 mm × 100 mm, pkg of 50 ea
Supelco
ORBO 609 Amberlite XAD®-2 (20/50) 400/200 mg, W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea
Supelco
ORBO 49P (OVS) Supelpak-20 specially treated Amberlite XAD®-2 (20/40), 270/140 mg, RC,GFF,F,F (specially cleaned) separators, O.D. × L 13-8 mm × 75 mm , OSHA Versatile Sampler (OVS) Tube, pkg of 10 ea
Supelco
ORBO 502 Activated Silica Gel (20/45) 100/50 mg, W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Supelco
ORBO 53 Activated Silica Gel (20/40) specially cleaned, 400/200 mg with Glass Fiber Filters, GFF,F,F separators, O.D. × L 7 mm × 100 mm, pkg of 50 ea
Supelco
ORBO 554 H2SO4 on Silica Gel (20/40) 150/75 mg, W,W,W separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Supelco
ORBO 80 Coated Filter, with cassettes unassembled
Supelco
ORBO 23 2-HMP on Amberlite XAD®-2 (20/40), 120/60 mg, W,W,W separators, O.D. × L 6 mm × 85 mm, pkg of 25 ea